The Controversial Role of IL-33 in Lung Cancer

被引:14
作者
Yang, Keshan [1 ]
Tian, Cheng [1 ]
Zhang, Chengliang [2 ]
Xiang, Ming [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Dept Pharmacol, Wuhan, Peoples R China
[2] Huazhong Sci andTechnol Univ, Dept Pharm Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
基金
中国国家自然科学基金;
关键词
IL-33; immune regulation; pulmonary fibrosis; lung cancer; dual regulation; PROPHYLACTIC CRANIAL IRRADIATION; TYROSINE KINASE INHIBITORS; ST2; GENE-PRODUCT; T-CELLS; VARIANT FORM; TUMOR-GROWTH; NK CELLS; C-MYC; EXPRESSION; CYTOKINE;
D O I
10.3389/fimmu.2022.897356
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interleukin-33 (IL-33) belongs to the interleukin-1 (IL-1) family, and its structure is similar to IL-18. When cells are damaged or undergo necrosis, mature form of IL-33 is secreted as a cytokine, which can activate the immune system and provide danger signals. The IL-33/ST2 signaling pathway is composed of IL-33, suppression of tumorigenicity 2 (ST2), and IL-1 receptor accessory protein (IL-1RAcP). IL-33 has been reported to be strongly associated with lung cancer progression, and can exhibit opposite effects on lung cancer under different conditions. In this review, we have summarized the structure and basic functions of IL-33, its possible function in immune regulation, and its role in pulmonary fibrosis as well as in lung cancer. We have highlighted the dual regulation of IL-33 in lung cancer and proposed potential lung cancer treatment regimens, especially new immunotherapies, based on its mechanism of action.
引用
收藏
页数:11
相关论文
共 110 条
[1]   Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer [J].
Akimoto, M. ;
Hayashi, J-I ;
Nakae, S. ;
Saito, H. ;
Takenaga, K. .
CELL DEATH & DISEASE, 2016, 7 :e2057-e2057
[2]   Management of Small Cell Lung Cancer Progress and Updates [J].
Altan, Mehmet ;
Chiang, Anne C. .
CANCER JOURNAL, 2015, 21 (05) :425-433
[3]   Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission [J].
Aupérin, A ;
Arriagada, R ;
Pignon, JP ;
Le Péchoux, C ;
Gregor, A ;
Stephens, RJ ;
Kristjansen, PEG ;
Johnson, BE ;
Ueoka, H ;
Wagner, H ;
Aisner, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07) :476-484
[4]  
Babadi Akbar Soleimani, 2019, Open Access Maced J Med Sci, V7, P45, DOI 10.3889/oamjms.2019.018
[5]   Predictors and Outcomes of Limited Resection for Early-Stage Non-Small Cell Lung Cancer [J].
Billmeier, Sarah E. ;
Ayanian, John Z. ;
Zaslavsky, Alan M. ;
Nerenz, David R. ;
Jaklitsch, Michael T. ;
Rogers, Selwyn O. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (21) :1621-1629
[6]   IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis [J].
Bilsborough, J ;
Leung, DYM ;
Maurer, M ;
Howell, M ;
Boguniewcz, M ;
Yao, L ;
Storey, H ;
LeCiel, C ;
Harder, B ;
Gross, JA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) :418-425
[7]  
Board P. A. T. E., 2021, PDQ Cancer Information Summaries
[8]   The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-γ production [J].
Bourgeois, Elvire ;
Van, Linh Pham ;
Samson, Michel ;
Diem, Severine ;
Barra, Anne ;
Roga, Stephane ;
Gombert, Jean-Marc ;
Schneider, Elke ;
Dy, Michel ;
Gourdy, Pierre ;
Girard, Jean-Philippe ;
Herbelin, Andre .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2009, 39 (04) :1046-1055
[9]   Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease [J].
Byers, Derek E. ;
Alexander-Brett, Jennifer ;
Patel, Anand C. ;
Agapov, Eugene ;
Dang-Vu, Geoffrey ;
Jin, Xiaohua ;
Wu, Kangyun ;
You, Yingjian ;
Alevy, Yael ;
Girard, Jean-Philippe ;
Stappenbeck, Thaddeus S. ;
Patterson, G. Alexander ;
Pierce, Richard A. ;
Brody, Steven L. ;
Holtzman, Michael J. .
JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (09) :3967-3982
[10]   Small Cell Lung Cancer: Where Do We Go From Here? [J].
Byers, Lauren Averett ;
Rudin, Charles M. .
CANCER, 2015, 121 (05) :664-672